|
Battle Lines Drawn in Brand vs. Generic Fight Over Cost-Saving Efforts in PDUFA Bills
Generic-drug makers have been rooting for a provision in the Senate’s FDA user fee bill that would expand access to REMS-restricted brand drugs to aid them in developing generic versions.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
|
Subscribe
Archives